deltatrials
Terminated PHASE3 INTERVENTIONAL NCT00286169

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer

Sponsor: Sumitomo Pharma Co., Ltd.

Conditions Small-cell Lung Cancer
Interventions Amrubicin Hydrochloride
Updated 7 times since 2017 Last updated: Apr 9, 2022 Started: Apr 30, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Sumitomo Pharma Co., Ltd.

More terminations from Sumitomo Pharma Co., Ltd.

Other Small-cell Lung Cancer trials with similar outcome

Browse all Small-cell Lung Cancer trials

Listed as NCT00286169, this PHASE3 trial focuses on Small-cell Lung Cancer and remains terminated or withdrawn. Sponsored by Sumitomo Pharma Co., Ltd., it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~May 2022 · 16 months · monthly snapshotTerminated~May 2022 – ~Jul 2024 · 26 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 11 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. May 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jan 2021 — May 2022 [monthly]

    Terminated PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sumitomo Pharma Co., Ltd.
Data source: Sumitomo Pharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations